In a unique, sweet partnership between two iconic Florida-based brands, TooJay’s Deli, and Lilly Pulitzer have teamed up to create a limited-edition Lemon Coconut Cake, celebrating Lilly Pulitzer’s ...

In a sweet team-up between two iconic Florida brands, TooJay’s Deli and Lilly Pulitzer have created a limited-edition Lemon Coconut Cake to celebrate Lilly Pulitzer’s 65th anniversary. You can now ...

KeyBanc analyst Ashley Owens maintained a Buy rating on Oxford Industries (OXM – Research Report) today and set a price target of $95.00.

Eli Lilly (LLY) is down -13.5%, or -$121.82 to $781.76. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks ...

Open to established writers and/or directors based in Chicago, IL, Lilly Wachowski’s home town, whose work aims to serve narratives that further Artistry, Diversity and Equity and uplift those ...

Pulitzer Prize-winning historian Anne Applebaum joins Chris Hayes to discuss how Trump has been talking like dictators of the past—and how this is a new thing for American politics. Oct. 23, 2024 ...

Those who follow my work closely know that I have been a big fan of pharmaceutical firm Eli Lilly and Company (NYSE:LLY) for a little while now. My first article about the company, published in ...

Lilly's Mounjaro to cost 2,200 Danish crowns per month Wegovy's price ranges from 1,313 to 2,353 crowns per month Denmark's public health system does not reimburse weight-loss drugs The two ...

According to a New York Times report this week, Eisai and Eli Lilly, in the clinical trials for their respective Alzheimer’s drugs Leqembi and Kisunla, genetically tested participants to ...

The 35-year-old mom is one of many patients taking a compounded version of tirzepatide produced by a pharmacy while Eli Lilly's brand-name versions, Zepbound and Mounjaro, have been in short supply.

Eli Lilly & Co’s Alzheimer’s drug won’t be made available for patients using England’s National Health Service, after the drug cost regulator deemed its benefits were too small to justify ...